Business Wire

Alexis Nasard to Join Kantar as CEO

19.10.2020 14:20:00 EEST | Business Wire | Press release

Share

Kantar, the world’s leading data, insights and consulting company, announces the appointment of Alexis Nasard as Chief Executive Officer, effective 30 December 2020.

Alexis Nasard joins Kantar with almost 30 years’ experience in the FMCG and retail world. Most recently Mr Nasard is currently CEO of Bata. Prior to that, Alexis spent six years at Heineken, culminating in the position of President of Western Europe Business and Global Chief Marketing Officer. Earlier, he worked for 17 years with Procter & Gamble, in a variety of marketing and general management roles.

Mr Nasard holds an MBA degree from UC Berkeley’s Haas School of Business, USA and an MS/BS degree in Civil Engineering from Saint Joseph University, Lebanon.

Of his appointment, Mr Nasard said “Throughout my career Kantar has been a trusted advisor. Kantar’s data, insights and advice informed many of the strategies, as well as communication and commercial plans my teams and I led. As much as I understand Kantar’s heritage and reputation today, it is our future that excites me most. The combination of Kantar’s deep understanding of consumers around the world, our proprietary data sets and our growing expertise in advanced analytics and artificial intelligence puts us in a leading position to reshape the insights and consulting market, whilst offering clients superior analytics they can monetize. This will be all the more relevant in the volatile and fluctuating environment we are living in as a consequence of the COVID-19 health and economic crisis, as clients need to operate on very steep learning curves.”

Announcing the appointment, Kantar Chairman Adam Crozier commented. “In Alexis we have appointed a world-class CEO. As a former CMO and client he understands the value Kantar delivers, and the role it plays in advising the world’s biggest consumer brands. Throughout his career Alexis has built a reputation for innovation, creativity and operational excellence. As we transform our business and position ourselves for growth, Alexis’ leadership and international experience will be instrumental in fulfilling the ambition that we have for Kantar.”

Christophe Jacobs, a Managing Director at Bain Capital Private Equity, added “This appointment is another important step on Kantar’s journey to become the world’s leading advisor on data-driven marketing and commercial strategies and a key ecosystem partner for global technology leaders. Mr Nasard understands first-hand the value such a strategy offers to the world’s leading consumer brands and has the creativity and operational experience to bring that strategy to life.“

-end-

About Kantar: Kantar is the world’s leading evidence-based insights and consulting company. We have a complete, unique and rounded understanding of how people think, feel and act; globally and locally in over 90 markets. By combining the deep expertise of our people, our data resources and benchmarks, our innovative analytics and technology, we help our clients understand people and inspire growth.

For more information visit: https://www.kantar.com/company-news/alexis-nasard-to-join-Kantar-as-CEO

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sam Mohr
kantar@axicom.com
02075090795

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye